Navigation Links
ADVENTRX Announces Appointment Of Chief Medical Officer
Date:8/14/2012

SAN DIEGO, Aug. 14, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Santosh J. Vetticaden, M.D., Ph.D., will join the Company as Chief Medical Officer and Senior Vice President.

Dr. Vetticaden has more than 25 years of experience in drug development and medicine.  His experience spans a variety of therapeutic areas, including anticoagulation, hemophilia, anti-infectives and rheumatology/inflammation.  He has directed and managed the clinical development of both large and small molecules, from protocol design to execution of multi-center, global clinical trials. 

Dr. Vetticaden has held several senior level positions leading drug development across phase 1 through phase 4 trials at biotech and large pharmaceutical companies.  Most recently, he served as Senior Vice President and Chief Medical and Development Officer at Cubist Pharmaceuticals, Inc., where his tenure was highlighted by successful phase 2 trials and advancing multiple drugs into phase 3.  At Cubist, he also played a significant role in the development and execution of new business strategy that resulted in significant product pipeline expansion.  Prior to joining Cubist, Dr. Vetticaden was Senior Vice President and Chief Medical Officer at Maxygen, Inc., where he had responsibilities and oversight for clinical development and regulatory affairs for all of the company's development programs, including Maxy-VIIa, which he progressed from the non-clinical stage through a phase 1 study in hemophilia, resulting in its outlicense to Bayer.  Before Maxygen, he held senior roles in drug development at Scios, Inc., a subsidiary of Johnson & Johnson, Aventis Pharmaceuticals (now Sanofi) and the Whitehall-Robins Healthcare division of American Home Products Corporation (now Pfizer).  Dr. Vetticaden has a Ph.D. in the areas of pharmacokinetics and pharmacodynamics from Virginia Commonwealth University; a M.D
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
2. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
3. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
4. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
5. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
6. FDAnews Announces Medical Device Mobile Apps Virtual Conference
7. Dehaier Medical Announces 2012 Second Quarter and Six Month Financial Results
8. Isis Pharmaceuticals Announces Redemption Of 2 5/8% Convertible Subordinated Notes Due 2027
9. WuXi PharmaTech Announces Second-Quarter 2012 Results
10. Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor
11. Comprehensive Care Corporation Announces Profitable Six Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015  Par Pharmaceutical Companies, ... conference call on Friday, March 13, 2015 at ... operations for the fourth quarter and full year ... and currently makes certain financial information available to ... and Exchange Commission and will make certain other ...
(Date:3/6/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... milestone payment from Biogen Idec related to advancing the ... in infants with spinal muscular atrophy (SMA).  ... is a randomized, double-blind, sham-procedure controlled thirteen month ... study will evaluate the efficacy and safety of a ...
(Date:3/5/2015)... March 5, 2015 WuXi PharmaTech (Cayman) Inc. ... capability and technology platform company serving the pharmaceutical, biotechnology, ... the United States, today announced its financial results for ... Fourth-Quarter 2014 Highlights , Net Revenues Increased ... Laboratory Services Net Revenues Grew 17.7% Year Over Year ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 4Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22
... presented at the 2008 iSBTc Annual Meeting -, ... a.m. ET to discuss,results -, BRANFORD, Conn., Nov. ... preliminary data from an ongoing Phase II,trial of CR011-vcMMAE, ... patients with unresectable Stage III or Stage IV melanoma.,Dr. ...
... Clinical Study of Paliperidone ER in this Under-Studied ... with schizoaffective,disorder receiving paliperidone extended release tablets (paliperidone ... their symptoms, according,to a new study presented today ... San Diego, Calif.(1) In addition, safety findings were ...
Cached Medicine Technology:CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6
(Date:3/6/2015)... York, NY (PRWEB) March 06, 2015 ... of “Women’s Health,” a campaign that seeks to educate, ... role when it comes to their health and their ... the rise, it has never been more pertinent to ... rights. , The print component of “Women’s Health” ...
(Date:3/6/2015)... March 06, 2015 “ Pokemini ” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review and shared ... , Over the last couple of years, mobile games ... the game. For example, Candy Crush allows users to connect ...
(Date:3/6/2015)... Ticket Down is a reputable source for ... the Moda Center. After being away from the touring ... no signs of letting up on his “Garth Brooks World ... wife, Trisha Yearwood, to venues around the United States. The ... acclaimed tour to the Moda Center in Portland, OR. The ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues ... organization has hired two new Scientific Program Officers, Amanda ... report to Grace Pavlath, Ph.D, who joined MDA late ... Director, and together will lead MDA as it accelerates ... for various types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 US Sports ... three Maryland camps – two non-contact specialty camps and ... run by Perfect Performance Training, located at Bowie State ... on developing position specific skills, speed and strength of ... at Salisbury University with Marvin Graves, former quarterback in ...
Breaking Medicine News(10 mins):Health News:The Well-Woman: Encouraging Regular Screenings and Advocating for Women’s Health Rights with Mediaplanet’s “Women’s Health” Campaign 2Health News:A Kawaii Social Game was Featured on NewsWatch Television on February 26, 2015 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2
... of genetics, environment caused mice to develop disease, study finds ... with mice, scientists have found a bacteria living in the ... rheumatoid arthritis. , The gut of all mammals is populated ... are essential for developing a normal immune system. But some ...
... Announcing a new Web ... to improve the look and strength of your abdominal muscles and improve overall health. Get ... site. , ... A new Web site has been developed to help anyone get in shape. If you ...
... ... to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA in Bayside, ... ... is pleased to announce the addition of Brian Safier, MD, Allergist/Immunologist, who will join ENTA ...
... ... Guidance Based on Experience at Pfizer, Merck, Medtronic, GTx, Johnson & Johnson, and the University ... ... 2010 -- To support its focus on regulatory compliance in the life sciences, openQ has ...
... now new areas in which whole body magnetic resonance imaging ... Deutsches rzteblatt International ( Dtsch Arztebl Int 2010; ... of possible uses, together with the limits of this radiation-free ... routine use in hospitals, as the procedure takes less than ...
... is an uncommon benign neoplasm with locally aggressive behavior but ... a 14-year-old patient with clinical presentations of abdominal pain and ... research article to be published on June 7, 2010 in ... A research team led by Professor Ko from Chang Gung ...
Cached Medicine News:Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 2Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 3Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 3Health News:openQ Announces the Formation of a Compliance Advisory Board 2Health News:openQ Announces the Formation of a Compliance Advisory Board 3
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn...
... The CoaguChek S System offers ... in just one minute requiring only ... enable you to provide more comprehensive ... with each patient. The CoaguChek S ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: